Plain-English translation of NCT06339619 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications—, , and —together as a second-line treatment for people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer) whose cancer stopped responding to initial immunotherapy combined with chemotherapy. The study aims to see whether this new combination can help shrink or stop the growth of the cancer and how safe it is for patients to take.
Although immunotherapy combined with chemotherapy is the standard first-line treatment for advanced esophageal cancer, most patients' cancers eventually stop responding and continue to grow. This medication combination is being explored as a potential second-line option to help patients whose cancer has become resistant to initial treatment.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug combination in 21-day treatment cycles: an intravenous infusion of one medication on day 1, plus two oral medications taken by mouth daily for 21 days. You would continue this treatment until your cancer stops responding, you experience intolerable side effects, or you decide to withdraw. Every 6 to 8 weeks, you would have imaging scans (such as CT scans) to check how well the treatment is working. The study plans to enroll about 32 patients total.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China